Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins

2016 ◽  
Vol 70 (3) ◽  
pp. 244-253 ◽  
Author(s):  
G. Hackett ◽  
A. H. Heald ◽  
A. Sinclair ◽  
P. W. Jones ◽  
R. C. Strange ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Replacement Therapy ◽  
Serum Testosterone ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Pde5 Inhibitors ◽  
All Cause Mortality ◽  
The Impact

Correction of Androgen Deficiency in Men with Type 2 Diabetes

2021 ◽  
Vol 16 ◽  
Author(s):  
Volodymyr Pankiv ◽  
Tetyana Yuzvenko ◽  
Nazarii Kobyliak ◽  
Ivan Pankiv
Keyword(s):  
Type 2 Diabetes ◽  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Control Group ◽  
Total Testosterone ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency ◽  
Testosterone Undecanoate ◽  
Testosterone Levels

Background: In men with low levels of testosterone in the blood, it is believed that the symptoms can be regarded as an association between testosterone deficiency syndrome and related comorbidities. Aim: to investigate the effectiveness of testosterone therapy in patients with type 2 diabetes (T2D) and androgen deficiency. Materials and methods: Testosterone replacement therapy was carried out in 26 men with T2D and clinically or laboratory-confirmed androgen deficiency. The age of the subjects ranged from 35 to 69 years old. Laboratory studies included determinations of the concentration of the hormones estradiol, luteinizing hormone (LH), and prostate-specific antigen (PSA). The observation period was 9 months. Results: The average level of total blood testosterone in the subjects before treatment was 9.4 mol/l and was likely lower than that of the control group (19.3 ± 1.6 nmol/l). The levels of total testosterone in the subjects ranged from 3.9 nmol/l to 10.7 nmol/l, and hormone levels measuring less than 8.0 nmol/l were observed in only 11 patients. After a course of testosterone replacement therapy, a stabilization in total testosterone levels at the level of reference values (as compared to the start of treatment) was observed in the blood of men with T2D after 9 months of observation and the administration of the fourth injection (16.83 ± 0.75 nmol/l). Conclusion: The use of long-acting injectable testosterone undecanoate leads to normalization of total testosterone levels in the blood of men with T2D and androgen deficiency, and LH levels in these patients are unlikely to change.

scholarly journals Testosterone Deficiency, Cardiac Health, and Older Men

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
G. Hackett ◽  
M. Kirby ◽  
A. J. Sinclair
Keyword(s):  
Type 2 Diabetes ◽  
Replacement Therapy ◽  
Risk Groups ◽  
Testosterone Replacement ◽  
Current Evidence ◽  
Testosterone Replacement Therapy ◽  
Testosterone Deficiency ◽  
Low Testosterone ◽  
Low Levels

Low levels of testosterone are manifested by erectile dysfunction, reduced sexual desire, and loss of morning erections with increasing numbers of men are being diagnosed and require treatment. The prevalence rates of testosterone deficiency vary according to different studies but may be as high as 40% in populations of patients with type 2 diabetes. There is increasing evidence that testosterone deficiency is associated with increased cardiovascular and all-cause mortality. Screening for low testosterone is recommended in a number of high risk groups including those with type 2 diabetes and metabolic syndrome. There are recent data to suggest that testosterone replacement therapy may reduce cardiovascular mortality as well as improving multiple surrogate markers for cardiovascular events. Specific clinical trials of testosterone replacement therapy are needed in selected populations but in the meantime we must treat patients based on the best current evidence.

scholarly journals Testosterone Replacement Therapy and the Risk of Hypoglycemia

2019 ◽  
Vol 2019 ◽  
pp. 1-5 ◽  
Author(s):  
Analía Verónica Yamaguchi ◽  
Pablo René Costanzo ◽  
Verónica Andrea Peuchot ◽  
Pablo Knoblovits
Keyword(s):  
Type 2 Diabetes ◽  
Drug Interaction ◽  
Replacement Therapy ◽  
Metabolic Control ◽  
Klinefelter Syndrome ◽  
Testosterone Replacement ◽  
Hypoglycemic Agents ◽  
Testosterone Replacement Therapy ◽  
History Of

We report the case of a 45-year-old man with a history of Klinefelter syndrome undergoing testosterone replacement therapy, and with type 2 diabetes treated with metformin with poor metabolic control. When vildagliptin was added to his treatment, he presented hypoglycemia after the testosterone injection. We highlight this not widely reported drug interaction between hypoglycemic agents and testosterone.

Sign in / Sign up

Export Citation Format

Share Document